IPdR

Drug Profile

IPdR

Alternative Names: Ropidoxuridine

Latest Information Update: 15 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Research Foundation of State University of New York; Yale University
  • Developer SuperGen
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaplastic astrocytoma; Hepatitis B; Herpes simplex virus infections; Solid tumours

Most Recent Events

  • 09 Jan 2007 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 09 Jun 2006 IPdR has received orphan drug status for malignant glioma in the US
  • 09 Jan 2006 Discontinued - Phase-II for Anaplastic astrocytoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top